Is human hepatocellular carcinoma a hormone-responsive tumor?
Open Access
- 1 January 2008
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 14 (11), 1682-9
- https://doi.org/10.3748/wjg.14.1682
Abstract
Before the positive results recently obtained with multitarget tyrosine kinase inhibitor sorafenib, there was no standard systemic treatment for patients with advanced hepatocellular carcinoma (HCC). Sex hormones receptors are expressed in a significant proportion of HCC samples. Following preclinical and epidemiological studies supporting a relationship between sex hormones and HCC tumorigenesis, several randomized controlled trials (RCTs) tested the efficacy of the anti-estrogen tamoxifen as systemic treatment. Largest among these trials showed no survival advantage from the administration of tamoxifen, and the recent Cochrane systematic review produced a completely negative result. This questions the relevance of estrogen receptor-mediated pathways in HCC. However, a possible explanation for these disappointing results is the lack of proper patients selection according to sex hormones receptors expression, but unfortunately the interaction between this expression and efficacy of tamoxifen has not been studied adequately. It has been also proposed that negative results might be explained if tamoxifen acts in HCC via an estrogen receptor-independent pathway, that requires higher doses than those usually administered, but an Asian RCT conducted to assess dose-response effect was completely negative. Interesting, preliminary results have been obtained when hormonal treatment (tamoxifen or megestrol) has been selected according to the presence of wild-type or variant estrogen receptors respectively, but no large RCTs are available to support this strategy. Negative results have been obtained also with anti-androgen therapy. In conclusion, there is no robust evidence to consider HCC a hormone-responsive tumor. Hormonal treatments should not be part of the current management of HCC.Keywords
This publication has 55 references indexed in Scilit:
- Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinomaHepatology Research, 2007
- Strategies for the management of hepatocellular carcinomaNature Clinical Practice Oncology, 2007
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Natural history of inoperable hepatocellular carcinoma: Estrogen receptors' status in the tumor is the strongest prognostic factor for survivalHepatology, 2000
- Review article: overview of medical treatments in unresectable hepatocellular carcinoma-an impossible meta-analysis?Alimentary Pharmacology & Therapeutics, 1998
- Effects of castration and androgen replacement on tumour growth of human hepatocellular carcinoma in nude miceJournal of Hepatology, 1996
- Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patientsGastroenterology, 1995
- Controlled trial of tamoxifen in patients with advanced hepatocellular carcinomaJournal of Hepatology, 1994
- Sex hormone receptors in hepatocellular carcinoma: Is there a rationale for hormonal treatment?Journal of Hepatology, 1993
- Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifenJournal of Hepatology, 1990